What is the mechanism of action of neratinib/neratinib? How to use it?

Neratinib/Neratinib is a tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR), HER2 and human epidermal growth factor receptor 4 (her 4) Positive cancer has anti-tumor effect. Neratinib is indicated as a single agent for the long-term adjuvant treatment of adult patients with early-stage HER2-positive breast cancer receiving adjuvant trastuzumab-based therapy. Neratinib, in combination with capecitabine, is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-her 2-based regimens in the metastatic setting.

Neratinibis an intracellular kinase inhibitor that irreversibly binds to epidermal growth factor receptor (EGFR), HER2 and HER4. In vitro, neratinib reduces EGFR and HER2 autophosphorylation, downstream MAPK and AKT signaling pathway and showed anti-tumor activity in cancer cell lines expressing EGFR and / or HER2. Neratinib human metabolitesM3, M6, M7 and M11< /span>Inhibits the activities of EGFR, HER2 and HER4 in vitro. In vivo, oral neratinib inhibited tumor growth in mouse xenograft models with tumor cell lines expressing HER2 and EGFR. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.